Muranushi, H., Kanda, J., Kobayashi, M., Maeda, T., Kitano, T., Tsuji, M., Ueda, Y., Ishikawa, T., Nohgawa, M., Watanabe, M., Imada, K., Moriguchi, T., Itoh, M., Ohno, H., Yonezawa, A., Hirata, H., Arima, N., Asagoe, K., Anzai, N., Nagata, K., Yasuno, S., Kuwabara, Y., Kitao, H., Kim, I., Kawagishi, K., Ueshima, K., Tominari, S., Nakayama, T., Yamashita, K., & Takaori-Kondo, A. (2022). bortezomib-cyclophosphamide-dexamethasone induction/consolidation and bortezomib maintenance for transplant-eligible newly diagnosed multiple myeloma: phase 2 multicenter trial. Hematology, 27(1), 239–248. http://access.bl.uk/ark:/81055/vdc_100180891210.0x000034